靶向髓源性抑制细胞与PD-L1揭示消融性大分割放疗优于常规分割放疗的免疫机制
该研究在免疫健全与免疫缺陷小鼠中比较同等生物等效剂量下消融性大分割放疗(AHFRT)与常规分割放疗(CFRT)的免疫改变。AHFRT在免疫健全而非免疫缺陷小鼠中显著抑制肿瘤生长,减少MDSC募集并下调其PD-L1,降低VEGF/VEGFR信号,联合抗PD-L1抗体疗效更佳,并延缓照射野外继发肿瘤生长。
要点
- AHFRT在免疫健全小鼠中显著抑制肿瘤生长,免疫缺陷小鼠中无此优势。
- AHFRT减少肿瘤内MDSC募集并下调其PD-L1,释放CD8+ T细胞毒性。
- AHFRT联合抗PD-L1抗体控制肿瘤生长和改善生存优于单用。
核心结论
- 靶向MDSC募集和增强抗肿瘤免疫是AHFRT疗效的关键。
- AHFRT联合抗PD-L1免疫治疗具有更强的抗肿瘤效力。
研究设计与样本
- 在免疫健全和免疫缺陷小鼠中,用同系肺癌和黑色素瘤细胞建立皮下肿瘤。
- 在相同生物等效剂量下分别给予AHFRT和CFRT治疗。
主要发现
- 与CFRT相比,AHFRT在免疫健全而非免疫缺陷小鼠中显著抑制肿瘤生长。
- AHFRT减少肿瘤内MDSC募集并降低这些细胞上PD-L1表达,释放CD8+ T细胞毒性。
- AHFRT通过下调VEGF抑制VEGF/VEGFR信号,该信号对MDSC募集至关重要。
- AHFRT联合抗PD-L1抗体在控制肿瘤生长和改善小鼠生存方面疗效更佳。
- AHFRT而非CFRT通过改变免疫调节显著延缓照射野外继发肿瘤生长。
临床怎么用
- AHFRT的疗效依赖免疫调节,联合抗PD-L1抗体可能增强抗肿瘤效果。
- AHFRT可能通过免疫机制延缓照射野外继发肿瘤生长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ablative hypofractionated radiation therapy (AHFRT) presents a therapeutic advantage compared with conventional fractionated radiation therapy (CFRT) for primary and oligometastatic cancers. However, the underlying mechanisms remain largely unknown. In the present study, we compared the immune alterations in response to AHFRT versus CFRT and examined the significance of immune regulations contributing to the efficacy of AHFRT. METHODS AND MATERIALS: We established subcutaneous tumors using syngeneic lung cancer and melanoma cells in both immunocompetent and immunocompromised mice and treated them with AHFRT and CFRT under the same biologically equivalent dose. RESULTS: Compared with CFRT, AHFRT significantly inhibited tumor growth in immunocompetent, but not immunocompromised, mice. On the cellular level, AHFRT reduced the recruitment of myeloid-derived suppressor cells (MDSCs) into tumors and decreased the expression of programmed death-ligand 1 (PD-L1) on those cells, which unlashed the cytotoxicity of CD8+ T cells. Through the downregulation of vascular endothelial growth factor (VEGF), AHFRT inhibited VEGF/VEGF receptor signaling, which was essential for MDSC recruitment. When combined with anti-PD-L1 antibody, AHFRT presented with greater efficacy in controlling tumor growth and improving mouse survival. By altering immune regulation, AHFRT, but not CFRT, significantly delayed the growth of secondary tumors implanted outside the irradiation field. CONCLUSIONS: Targeting MDSC recruitment and enhancing antitumor immunity are crucial for the therapeutic efficacy of AHFRT. When combined with anti-PD-L1 immunotherapy, AHFRT was more potent for cancer treatment.
引用
- Lan J, Li R, Yin LM, et al. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29619980. doi:10.1016/j.ijrobp.2018.01.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。